IS6970A - Lyfjablanda á föstu formi sem felur í sér 4-sýanó-tríflúor-3-(4-flúorfenýlsúlfonýl)-2-hýdroxý-2-metýlprópíón-m-tólúidíð og PVP - Google Patents

Lyfjablanda á föstu formi sem felur í sér 4-sýanó-tríflúor-3-(4-flúorfenýlsúlfonýl)-2-hýdroxý-2-metýlprópíón-m-tólúidíð og PVP

Info

Publication number: IS6970A
Authority: IS; Iceland
Prior art keywords: drug; alpha; toluidide; pvp; trifluoro
Prior art date: 2001-04-02

Application number

IS6970A

Other languages

English (en)

Inventor

Kay Cahill Julie

Frances Bateman Nicola

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-02

Filing date

2003-09-29

Publication date

2003-09-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27354679&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS6970(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-04-02 Priority claimed from SE0101171A external-priority patent/SE0101171D0/xx

2001-09-04 Priority claimed from SE0102957A external-priority patent/SE0102957D0/xx

2001-10-25 Priority claimed from SE0103565A external-priority patent/SE0103565D0/xx

2003-09-29 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2003-09-29 Publication of IS6970A publication Critical patent/IS6970A/is

Links

238000009472 formulation Methods 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
-1 4-fluorophenylsulfonyl Chemical group 0.000 title 1
239000007787 solid Substances 0.000 title 1
239000003814 drug Substances 0.000 abstract 7
229940079593 drug Drugs 0.000 abstract 7
239000007962 solid dispersion Substances 0.000 abstract 2
206010060862 Prostate cancer Diseases 0.000 abstract 1
208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000036470 plasma concentration Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

IS6970A 2001-04-02 2003-09-29 Lyfjablanda á föstu formi sem felur í sér 4-sýanó-tríflúor-3-(4-flúorfenýlsúlfonýl)-2-hýdroxý-2-metýlprópíón-m-tólúidíð og PVP IS6970A (is)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
SE0101171A SE0101171D0 (sv)	2001-04-02	2001-04-02	Pharmaceutical formulation
SE0102957A SE0102957D0 (sv)	2001-09-04	2001-09-04	Pharmaceutical formulation
SE0103565A SE0103565D0 (sv)	2001-10-25	2001-10-25	Pharmaceutical formulation
PCT/GB2002/001439 WO2002080902A1 (en)	2001-04-02	2002-03-27	Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp

Publications (1)

Publication Number	Publication Date
IS6970A true IS6970A (is)	2003-09-29

Family

ID=27354679

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS6970A IS6970A (is)	2001-04-02	2003-09-29	Lyfjablanda á föstu formi sem felur í sér 4-sýanó-tríflúor-3-(4-flúorfenýlsúlfonýl)-2-hýdroxý-2-metýlprópíón-m-tólúidíð og PVP

Country Status (21)

Country	Link
US (1)	US20040138299A1 (is)
EP (1)	EP1381358B1 (is)
JP (1)	JP2004525164A (is)
KR (1)	KR20030087048A (is)
CN (1)	CN1536993A (is)
AT (1)	ATE324886T1 (is)
BR (1)	BR0208421A (is)
CA (1)	CA2443040A1 (is)
CZ (1)	CZ20032647A3 (is)
DE (1)	DE60211139T2 (is)
EE (1)	EE200300476A (is)
ES (1)	ES2261655T3 (is)
HU (1)	HUP0303454A3 (is)
IL (1)	IL157955A0 (is)
IS (1)	IS6970A (is)
MX (1)	MXPA03008999A (is)
NO (1)	NO20034386L (is)
NZ (1)	NZ528284A (is)
PL (1)	PL365330A1 (is)
SK (1)	SK12032003A3 (is)
WO (1)	WO2002080902A1 (is)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK10722003A3 (sk) *	2001-02-27	2004-02-03	Astrazeneca Ab	Farmaceutická formulácia obsahujúca bicalutamid v pevnej disperzii s enterickým polymérom a jej použitie
SE0103424D0 (sv) *	2001-10-15	2001-10-15	Astrazeneca Ab	Pharmaceutical formulation
SE0103838D0 (sv) *	2001-11-16	2001-11-16	Astrazeneca Ab	Pharmaceutical formulation & product
US20050008691A1 (en) *	2003-05-14	2005-01-13	Arturo Siles Ortega	Bicalutamide compositions
CA2589265A1 (en) *	2004-11-29	2006-06-01	Novartis Ag	Dosage regimen of an s1p receptor agonist
WO2006090129A2 (en) *	2005-02-23	2006-08-31	Astrazeneca Ab	Bicalutamide for delivering increasing steady state plasma levels
US7785629B2 (en) *	2005-06-21	2010-08-31	Helm Ag	Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof
CN101272769B (zh) *	2005-07-28	2013-04-24	Isp投资有限公司	生物利用度提高的苯醌类化合物
US20080045600A1 (en) *	2006-08-17	2008-02-21	Gawande Rahul S	Bicalutamide compositions
WO2008076780A2 (en) *	2006-12-14	2008-06-26	Isp Investments Inc.	Amorphous valsartan and the production thereof
US10189957B2 (en) *	2007-01-26	2019-01-29	Isp Investments Llc	Formulation process method to produce spray dried products
DK2278960T4 (da)	2008-03-17	2020-01-27	Actelion Pharmaceuticals Ltd	Dosisregimen til en selektiv sip1 receptoragonist
US9018253B2 (en)	2010-07-02	2015-04-28	Bio-Pharm Solutions Co., Ltd.	Phenylcarbamate compound and muscle relaxant containing the same
CN103282346B (zh)	2011-01-13	2014-11-19	比皮艾思药物研发有限公司	用于制备苯基氨基甲酸酯衍生物的方法
EP2797879B1 (en)	2011-12-27	2018-12-26	Bio-Pharm Solutions Co., Ltd.	Phenyl carbamate compounds for use in alleviating or treating pain and neuropathic pain
TW201431570A (zh)	2012-11-22	2014-08-16	Ucb Pharma Gmbh	用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
US10046151B2 (en)	2013-07-03	2018-08-14	Lts Lohmann Therapie-Systeme, Ag	Transdermal therapeutic system with electronic component
WO2015177212A1 (en)	2014-05-20	2015-11-26	Lts Lohmann Therapie-Systeme Ag	Transdermal delivery system including an interface mediator
US11633367B2 (en) *	2014-05-20	2023-04-25	Lts Lohmann Therapie-Systeme Ag	Transdermal delivery system containing rotigotine
WO2015177209A1 (en)	2014-05-20	2015-11-26	Lts Lohmann Therapie-Systeme Ag	Method for adjusting the release of active agent in a transdermal delivery system
ES2839128T3 (es)	2014-12-05	2021-07-05	Aragon Pharmaceuticals Inc	Composiciones anticancerosas
MX381829B (es)	2014-12-05	2025-03-13	Aragon Pharmaceuticals Inc	Composiciones anticancerígenas.
RS66323B1 (sr)	2014-12-05	2025-01-31	Aragon Pharmaceuticals Inc	Sastavi protiv raka

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0748220A4 (en) *	1994-01-21	1997-09-10	Sepracor Inc	METHOD AND COMPOSITIONS FOR TREATING ANDROGEN-DEPENDENT DISEASES USING OPTICALLY PURE R - (-) CASODEX
DE60039379D1 (de) *	1999-02-10	2008-08-21	Pfizer Prod Inc	Pharmazeutische feste Dispersionen
GB9930839D0 (en) *	1999-12-30	2000-02-16	Pharmacia & Upjohn Spa	Process for treating gynecomastia

2002
- 2002-03-27 WO PCT/GB2002/001439 patent/WO2002080902A1/en not_active Ceased
- 2002-03-27 MX MXPA03008999A patent/MXPA03008999A/es unknown
- 2002-03-27 NZ NZ528284A patent/NZ528284A/en unknown
- 2002-03-27 SK SK1203-2003A patent/SK12032003A3/sk unknown
- 2002-03-27 HU HU0303454A patent/HUP0303454A3/hu unknown
- 2002-03-27 PL PL02365330A patent/PL365330A1/xx not_active Application Discontinuation
- 2002-03-27 CZ CZ20032647A patent/CZ20032647A3/cs unknown
- 2002-03-27 ES ES02718317T patent/ES2261655T3/es not_active Expired - Lifetime
- 2002-03-27 BR BR0208421-0A patent/BR0208421A/pt not_active IP Right Cessation
- 2002-03-27 AT AT02718317T patent/ATE324886T1/de not_active IP Right Cessation
- 2002-03-27 DE DE60211139T patent/DE60211139T2/de not_active Expired - Fee Related
- 2002-03-27 US US10/473,709 patent/US20040138299A1/en not_active Abandoned
- 2002-03-27 EP EP02718317A patent/EP1381358B1/en not_active Revoked
- 2002-03-27 CA CA002443040A patent/CA2443040A1/en not_active Abandoned
- 2002-03-27 EE EEP200300476A patent/EE200300476A/xx unknown
- 2002-03-27 KR KR10-2003-7012900A patent/KR20030087048A/ko not_active Withdrawn
- 2002-03-27 CN CNA028077474A patent/CN1536993A/zh active Pending
- 2002-03-27 JP JP2002578941A patent/JP2004525164A/ja active Pending
- 2002-03-27 IL IL15795502A patent/IL157955A0/xx unknown
2003
- 2003-09-29 IS IS6970A patent/IS6970A/is unknown
- 2003-10-01 NO NO20034386A patent/NO20034386L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NZ528284A (en)	2005-04-29
WO2002080902A1 (en)	2002-10-17
CZ20032647A3 (cs)	2004-09-15
US20040138299A1 (en)	2004-07-15
IL157955A0 (en)	2004-03-28
MXPA03008999A (es)	2004-02-12
DE60211139T2 (de)	2007-03-01
CN1536993A (zh)	2004-10-13
ES2261655T3 (es)	2006-11-16
NO20034386L (no)	2003-11-28
PL365330A1 (en)	2004-12-27
SK12032003A3 (sk)	2004-03-02
EP1381358B1 (en)	2006-05-03
ATE324886T1 (de)	2006-06-15
JP2004525164A (ja)	2004-08-19
NO20034386D0 (no)	2003-10-01
HUP0303454A2 (hu)	2004-01-28
DE60211139D1 (de)	2006-06-08
EE200300476A (et)	2003-12-15
HUP0303454A3 (en)	2005-12-28
EP1381358A1 (en)	2004-01-21
BR0208421A (pt)	2004-03-30
KR20030087048A (ko)	2003-11-12
CA2443040A1 (en)	2002-10-17

Publication	Publication Date	Title
IS6970A (is)	2003-09-29	Lyfjablanda á föstu formi sem felur í sér 4-sýanó-tríflúor-3-(4-flúorfenýlsúlfonýl)-2-hýdroxý-2-metýlprópíón-m-tólúidíð og PVP
WO2002067893A3 (en)	2003-01-16	Pharmaceutical formulation comprising bicalutamide
IL154888A (en)	2013-12-31	Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
MXPA03011538A (es)	2004-03-09	Composicion medicinal que sustancialmente no causaria dano a la mucosa intestinal.
ATE442142T1 (de)	2009-09-15	Fredericamycin-derivate als arzneimittel zur tumorbehandlung
CY1109681T1 (el)	2014-08-13	Υποκατεστημενα παραγωγα κιναζολινης ως αναστολεις των κινασων aurora
HU0102039D0 (en)	2001-07-30	Use of paclitaxel stabilized with albumin for the preparation of pharmaceutical compositions treating solid tumors and the pharmaceutical compositions obtained thereby
ATE468332T1 (de)	2010-06-15	Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin- - yi)aminderivate
NO20034204D0 (no)	2003-09-22	Farmasöytiske kombinasjoner til behandling av kreft
MXPA05011076A (es)	2006-01-24	Derivados de quinazolina para el tratamiento de cancer.
DK1256339T3 (da)	2004-02-09	Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom
SE0101932D0 (sv)	2001-05-31	Pharmaceutical combinations
TW200505452A (en)	2005-02-16	Chemical compounds
ATE478662T1 (de)	2010-09-15	Arzneilösungen enthaltend modafinilverbindungen
SE0103424D0 (sv)	2001-10-15	Pharmaceutical formulation
SE0103839D0 (sv)	2001-11-16	Pharmaceutical formulation & product
DE60222383D1 (de)	2007-10-25	Medikament zur verabreichung von amifostin und verwandten wirkstoffen
MXPA04001912A (es)	2004-07-23	Aminobenzofenonas novedosas.
EA200200853A1 (ru)	2003-02-27	Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
SE0103838D0 (sv)	2001-11-16	Pharmaceutical formulation & product
NO20026032D0 (no)	2002-12-16	Farnesyltransferasehemmende 1,2-annelert kinolinenantiomer
SE0102887D0 (sv)	2001-08-29	New formulation
HRP20080597T3 (en)	2008-12-31	Cancer combination therapy comprising azd2171 and zd1839
DK1071425T3 (da)	2007-12-27	Behandling af depression og farmaceutiske præparater dertil
BR0213463A (pt)	2004-11-09	Composições farmacêuticas contendo macrólidos